This article was originally published by Andrew M Hill, Melissa J Barber, and Dzintars Gotham in BMJ Global Health Jan 2018, 3 (1) e000571 under a Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license. Abstract Introduction There are persistent gaps in access…
Posts published in “Guest Content”
Decision-making in product portfolios of pharmaceutical research and development – managing streams of innovation in highly regulated markets
0
This article was originally published by Antti Jekunen in Drug Des Devel Ther. 2014; 8: 2009–2016 under a Creative Commons Attribution – Non Commercial (unported, v3.0) License. Abstract Decision-making is a core function…
Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs As Cancer Therapeutics
0
Originally published by J. Javier Hernandez, Michael Pryszlak, Lindsay Smith, Connor Yanchus, Naheed Kurji, Vijay M. Shahani and Steven V. Molinski in Front. Oncol., 14 November 2017. Abstract The repositioning or…
Originally published by Er J. Wouters, Panos G. Kavanos, Martin McKee in The Milbank Quarterly, 95: 554–601 under a Creative Commons License. Abstract Policy Points: Our study indicates that there are opportunities…
This article was originally published by Ekaterina Galkina Cleary, Jennifer M. Beierlein, Navleen Surjit Khanuja, Laura M. McNamee and Fred D. Ledley in PNAS under a Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC…
This article was originally published by Christopher Southan, Peter Varkonyi, Kiran Boppana, Sarma A.R.P. Jagarlapudi, and Sorel Muresan at PLoS ONE 8(10): e77142. Abstract The statistics of drug development output and…
Celgene vs. Dr. Reddy’s Revlimid patent infringement case depends on polymorph stability; lack thereof may favor Celgene position – experts
0
This article was originally published on November 30th 2017 by Hamish McDougall and Alaric DeArment of BioPharm Insight, part of GlobalData. Polymorph differences support noninfringement argument Trace solvate amount could destabalise…
Consumer access to effective and affordable medicines is an imperative for public health, social equity, and economic development, but this need is not being served adequately by the biopharmaceutical sector,…
This article was originally published by Himanshu Gupta, Suresh Kumar, Saroj Kumar Roy, and R. S. Gaud at J Pharm Bioallied Sci. 2010 Jan-Mar; 2(1): 2–7. Abstract It is widely recognized…
We must achieve a balance between the current and future needs of patients and the timely introduction of existing and new pharmaceutical drugs Dr. Ashish Bharadwaj is a faculty member at…
